Dr. Steve Rubinstein OD
Optometrist, Sound Shore Vision Care
Member of the Healthcare Council
Council Member Biography
Steve Rubinstein, OD, is a Clinical Optometrist at Diamond District Eye Associates and Sound Shore Vision Center, office based practices in New York. Dr. Rubinstein has a biochemical background. He has won the Frank R. Blood award by the Society of Toxicology for the best paper in this peer reviewed publication. Dr. Rubinstein is also an adviser with Cancer Care, Inc. and presents to groups of patients as a cancer survivor. He has interest in ocular evaluation of glaucoma using coherent lasers. Dr. Rubinstein has been a consultant to a large laser vision correction practice in New York City. (This is me - Update Profile)
Employment History
- 2007 - Unspecified
- Optometrist, Sound Shore Vision Care
- 1989 - Unspecified
- Optometrist, Diamond District Eye Associates
GLG NewsSM Analyses by Steve Rubinstein
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
July 2010...B+L Voluntarily Recalls ReNu Multi-Purpose Solution
July 10, 2010
B+L Voluntarily Recalls Certain ReNu Multi-Purpose Solution and ReNu MultiPlus Multi-Purpose Solution in Europe and Middle East | www.visionmonday.com
No this is not 2007! A new problem has occurred in the manufacturing of Baucsh & Lomb's current signature contact lens disinfecting product, ReNu. Bausch has just released BioTrue, the next best product in Contact Lens care about 2 weeks ago.
-
Abbott back in contact lens solution game
June 12, 2010
Abbott back in contact lens solution game | www.chicagobreakingbusiness.com
There are new regulations and new contact lens solutions being announced almost weekly. Both Abbott and Bausch & Lomb have released new information on contact lens solutions. The industry leader Alcon's OptiFree with almost 33% of the retail US market should announce a new solution soon.
-
New Contact Lens Products in the Pipeline From J&J (JNJ)
June 4, 2010
UPDATE 3-J&J sees fast-growing device market | www.reuters.com
At the 2nd qtr reports for Johnson & Johnson Vision (JNJ) products a new announcement for allergy sufferers can lead to a new vehicle for introduction of medications in the eye, and the whole body.
-
Alcon Expanding Its Drug Offerings and Pipeline with 3 Medications
January 20, 2010
Alcon to purchase rights for two eye care products from Sirion Therapeutics | www.pharmabiz.com
The rights for the the new anti inflammatory medication Durezol is Hot. The rights for Zirgan is a much smaller market, but there is limited competition in that field.The New Dry Eye Syndrome medication for Ocular Surface Disease is the first potential since the blockbuster medication Restasis. This is undergoing clinical clinical testing now. There are one or two other Dry Eye Syndrome medications coming down the pipeline.
-
Alcon would make a nice prize for Novartis
January 4, 2010
Top News Bloomberg Novartis May Sell Bonds in 2010 for $28.2 Billion Alcon Deal | www.businessweek.com
It looks like Novartis AG is gearing up to purchase the rest of Alcon, Inc.
GLG Study Groups with Steve Rubinstein(?)
GLG Live Meetings with Steve Rubinstein(?)
Steve Rubinstein has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.